- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenetics of anthracyclines
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 17, Issue 9, Pages 1075-1087
Publisher
Future Medicine Ltd
Online
2016-06-08
DOI
10.2217/pgs-2016-0036
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evidence for association of SNPs inABCB1andCBR3, but notRAC2, NCF4, SLC28A3orTOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines
- (2016) Daniel L Hertz et al. PHARMACOGENOMICS
- Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity
- (2015) Eric S. Christenson et al. CLINICAL BIOCHEMISTRY
- A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
- (2015) Folefac Aminkeng et al. NATURE GENETICS
- SLC transporters as therapeutic targets: emerging opportunities
- (2015) Lawrence Lin et al. NATURE REVIEWS DRUG DISCOVERY
- Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors
- (2015) Elżbieta Sadurska PEDIATRIC CARDIOLOGY
- Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20+ B-cell lymphoma
- (2015) Annegret Reichwagen et al. PHARMACOGENOMICS
- Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms
- (2015) Luc Rochette et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cardiotoxicity and Cardioprotection in Childhood Cancer
- (2014) Steven E. Lipshultz et al. ACTA HAEMATOLOGICA
- Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management
- (2014) Judy Truong et al. CANADIAN JOURNAL OF CARDIOLOGY
- Cardio-Oncology Issues Among Pediatric Cancer and Stem Cell Transplant Survivors
- (2014) Jessica C. Hochberg et al. Cardiology in Review
- The emerging era of pharmacogenomics: current successes, future potential, and challenges
- (2014) J.W. Lee et al. CLINICAL GENETICS
- Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology Group
- (2014) Xuexia Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevention of Anthracycline-Induced Cardiotoxicity
- (2014) Pimprapa Vejpongsa et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy
- (2014) Kasey Leger et al. PEDIATRIC BLOOD & CANCER
- In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia
- (2014) A Gézsi et al. PHARMACOGENOMICS JOURNAL
- Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
- (2014) Tomáš Šimůnek et al. Pharmacological Reports
- Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia
- (2013) Steven E. Lipshultz et al. CANCER
- Occult Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy
- (2013) Olga H. Toro-Salazar et al. Circulation-Cardiovascular Imaging
- Anthracycline-related cardiotoxicity in childhood cancer survivors
- (2013) Steven E. Lipshultz et al. CURRENT OPINION IN CARDIOLOGY
- Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer
- (2013) Gregory T. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Anthracycline-Related Cardiac Histological Lesions With NADPH Oxidase Functional Polymorphisms
- (2013) A. Cascales et al. ONCOLOGIST
- Reduced cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia
- (2013) Emily S. Tonorezos et al. PEDIATRIC BLOOD & CANCER
- Validation of variants inSLC28A3andUGT1A6as genetic markers predictive of anthracycline-induced cardiotoxicity in children
- (2013) H. Visscher et al. PEDIATRIC BLOOD & CANCER
- Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity
- (2013) Brian C Jensen et al. PHARMACOGENOMICS
- Roles of Genetic Polymorphisms in the Folate Pathway in Childhood Acute Lymphoblastic Leukemia Evaluated by Bayesian Relevance and Effect Size Analysis
- (2013) Orsolya Lautner-Csorba et al. PLoS One
- Cardiac Complications of Oncologic Therapy
- (2013) Christopher M. Walker et al. RADIOGRAPHICS
- Cancer Pharmacogenomics in Children: Research Initiatives and Progress to Date
- (2013) Shahrad Rod Rassekh et al. PEDIATRIC DRUGS
- A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor
- (2013) Joanna M. Lubieniecka et al. Frontiers in Genetics
- Single-Nucleotide Polymorphisms in Aldo-Keto and Carbonyl Reductase Genes Are Not Associated with Acute Cardiotoxicity after Daunorubicin Chemotherapy
- (2012) J. M. Lubieniecka et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods
- (2012) Davide Pirolli et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms
- (2012) Bilge Volkan Salanci et al. JOURNAL OF CHEMOTHERAPY
- High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors
- (2012) Helena J. van der Pal et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of the molecular basis of doxorubicin-induced cardiotoxicity
- (2012) Sui Zhang et al. NATURE MEDICINE
- NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones
- (2011) David Siegel et al. BIOCHEMICAL PHARMACOLOGY
- Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma
- (2011) Rachael E. Windsor et al. CANCER
- NAD(P)H:Quinone Oxidoreductase 1 and its Potential Protective Role in Cardiovascular Diseases and Related Conditions
- (2011) Hong Zhu et al. Cardiovascular Toxicology
- ABCC1polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia
- (2011) Agnes F. Semsei et al. CELL BIOLOGY INTERNATIONAL
- Pharmacogenetics of genes across the doxorubicin pathway
- (2011) David Jamieson et al. Expert Opinion on Drug Metabolism & Toxicology
- Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
- (2011) Henk Visscher et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group
- (2011) Javier G. Blanco et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer
- (2011) Barry H. Trachtenberg et al. PEDIATRIC CARDIOLOGY
- Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review
- (2010) Suman Lal et al. CURRENT DRUG METABOLISM
- Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation
- (2010) Almudena Cascales et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Doxorubicin pathways
- (2010) Caroline F. Thorn et al. Pharmacogenetics and Genomics
- Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity
- (2009) Yunfang Zhang et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- New Developments in Anthracycline-Induced Cardiotoxicity
- (2009) A. Mordente et al. CURRENT MEDICINAL CHEMISTRY
- Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21
- (2009) D Rossi et al. LEUKEMIA
- Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood
- (2009) Vladan Rajić et al. LEUKEMIA & LYMPHOMA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started